Read the latest insights we've been sharing on LinkedIn
April 4, 2024
Real Endpoints at ASX2024
by Real Endpoints
Asembia24 is less than one month away. Don't gamble with your market access needs. Connect with the Real Endpoints team: Jeff Berkowitz, Susan Raiola, Rob O'Brien, Ryan Walsh, and Jeff Parish. We'll be on the ground in Las Vegas starting April 28.
LinkedIn >
March 28, 2024
New data from Real Endpoints demonstrates the real-world value of RE Assist, a proprietary AI-enabled platform for patient copay support
by Real Endpoints
There's been much discussion about just how much impact lowering of out-of-pocket maximums, a major feature of the Part D redesign, will have on patient affordability. Data from RE Assist, our AI-based platform that identifies and validates new sources of copay and deductible foundation support, suggests that even with lower OOP maximums, patients will continue struggle to afford their meds.
LinkedIn >
March 18, 2024
by Real Endpoints
The Real Endpoints team is taking on PCMA today and tomorrow in Orlando. Would love to touch base if you are attending!
LinkedIn >
March 1, 2024
Rare Disease Day 2024
by Real Endpoints
At Real Endpoints, Rare Disease Day isn't just another awareness day—it's personal. Many of us here have been directly touched by the challenges and triumphs associated with living with a rare disease, whether through personal experience or those of friends and loved ones.
LinkedIn >
February 27, 2024
PR Newswire: press release distribution, targeting, monitoring and marketing
by Real Endpoints
The team at Real Endpoints has been working tirelessly to improve RE Assist, a simple, easy-to-use AI-based platform designed to solve a critical gap in the market: providing patients with real-time information about available third-party foundation dollars for prescription meds.
LinkedIn >
February 19, 2024
Are We Valuing Prescription Drugs Appropriately?
by Real Endpoints
This new Health Affairs Forefront article explains in simple language why it's past time to update the methodology underpinning how we value - and ultimately price - drugs.
read full article >